Sexual medicine, sexual bodies and the ‘pharmaceutical imagination

Science as Culture

Volumn 18, Issue 2, 2009, Pages 133-149

  Marshall, Barbara L ^a  

^a TRENT UNIVERSITY   (Canada)

Author keywords

Biomedicine; Pharmaceuticals; Sexual dysfunction

Indexed keywords

EID: 84861652287     PISSN: 09505431     EISSN: 14701189     Source Type: Journal    
DOI: 10.1080/09505430902885466     Document Type: Article

References (85)

1. Akrich, M., and Latour, B., 1992. “ A summary of a convenient vocabulary for the semiotics of human and non-human assemblies ”. In Shaping Technology/Building Society:Studies in Sociotechnical Change, Edited by:Bijker, W., and Law, J., 259–264. Cambridge, MA:MIT Press.
2. Azam, U., 2006. Late-stage clinical development in lower urogenital targets:sexual dysfunction. British Journal of Pharmacology, 147:S153–159.
3. Bachman, G., Bancroft, J., Braunstein, G., Burger, H. G., Davis, S., Dennerstein, L., Goldstein, I., Guay, A., Leiblum, S., Lobo, R. A., Notelovitz, M., Rosen, R. C., Sarrel, P. M., Sherwin, B., Simon, J. A., Simpson, G. M., Shifren, J. L., Spark, R., and Traish, A., 2002. Female androgen insufficiency:the Princeton consensus statement on definition, classification and assessment. Fertility and Sterility, 77 (4):660–665.
4. Ballard, K., and Elston, M. A., 2005. Medicalisation:a multi-dimensional concept. Social Theory and Health, 3:228–241.
5. Barad, K., 1998. Getting real:technoscientific practices and the materialization of reality. Differences:A Journal of Feminist Cultural Studies, 10 (2):87–128.
6. Berenson, A., 2006. A daily pill to combat impotence?. New York Times, 13 June
7. Berman, J., and Bassuk, J., 2002. Physiology and pathophysiology of female sexual function. World Journal of Urology, 20:111–118.
8. Berman, J., Berman, L., and Kanaly, K., 2003. Female sexual dysfunction:new perspectives on anatomy, physiology, evaluation and treatment. EAU Update Series, 1:166–177.
9. Berman, J., Berman, L., Lin, E., Flaherty, E. E., Lahey, N., Goldstein, I., and Cantey-Kiser, J., 2001. Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. Journal of Sex and Marital Therapy, 27:411–420.
10. Braunstein, G. D., 2002. Androgen insufficiency in women:summary of critical issues. Fertility and Sterility, 4 (Supp. 4):S94–S99.
11. Caruso, S., Intelisano, G., Lupo, L., and Agnello, C., 2001. Premenopausal women affected by sexual arousal disorder treated with sildenafil:a double blind, cross-over, placebo-controlled study. British Journal of General Practice, 108:623–628.
12. Center for Medical Consumers. 2003. Male and female sexual dysfunction:how effective are the drugs. Health Facts,:1–2.
13. Clarke, A. E., Shim, J. K., Mamo, L., Fosket, J. R., and Fishman, J. R., 2003. Biomedicalization:technoscientific transformations of health, illness and US biomedicine. American Sociological Review, 68:161–194.
14. Comeau, P., 2005. Does your libido need a boost?. The Globe and Mail, 1 October:F9
15. Conrad, P., 2005. The shifting engines of medicalization. Journal of Health and Social Behavior, 46 (1):3–14.
16. D'Amati, G., di Gioia, C. R. T., Pannunzi, L. P., Pistilli, D., Carosa, E., Lenzi, A., and Jannini, E. A., 2003. Functional anatomy of the human vagina. Journal of Endocrinological Investigation, 26 (3):92–96.
17. Davis, S. R., Davidson, S. L., Donath, S., and Bell, R. J., 2005. Circulating androgen levels and self-reported sexual function in women. Journal of the American Medical Association, 294 (1):91–96.
18. Diamond, L. E., Earle, D. C., Heiman, J. R., Rosen, R. C., Perelman, M. A., and Harning, R., 2006. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by Bremelanotide (PT-141), a melanocortin receptor agonist. Journal of Sexual Medicine, 3:628–638.
19. Enserink, M., 2005. Let's talk about sex—and drugs. Science, 10 June:1578–1580.
20. Fausto-Sterling, A., 2005. The bare bones of sex:Part 1—sex and gender. Signs, 30 (2):1492–1597.
21. Fishman, J., 2004. Manufacturing desire:the commodification of female sexual dysfunction. Social Studies of Science, 34 (2):187–218.
22. Fitzpatrick, M., 2006. The men's health movement:a morbid symptom. Journal of Men's Health and Gender, 3 (3):258–262.
23. Foucault, M., 1975. The Birth of the Clinic:An Archaeology of Medical Perception, New York:Vintage Books.
24. Fraser, M., Kember, S., and Lury, C., 2005. Inventive life:approaches to the new vitalism. Theory, Culture and Society, 22 (1):1–14.
25. Freud, S., 1905/1953. The Standard Edition of the Complete Psychological Works of Sigmund Freud, London:Hogarth Press.
26. Goldstein, I., and Berman, J., 1998. Vasculogenic female sexual dysfunction:vaginal engorgement and clitoral erectile insufficiency syndromes. International Journal of Impotence Research, 10 (Suppl. 2):S84–S90.
27. Gomart, E., 2002. Methadone:six effects in search of a substance. Social Studies of Science, 32 (1):93–135.
28. Greenslit, N., 2002. Pharmaceutical branding:identity, individuality and illness. Molecular Interventions, 2:342–345.
29. Groopman, J. E., 2002. Hormones for men:is male menopause a question of medicine or of marketing?. New Yorker, 29 July
30. Haraway, D., 1991. Simians, Cyborgs and Women, London:Routledge.
31. tm:Feminism and Technoscience, New York:Routledge.
32. Healy, D., 1997. The Antidepressant Era, Cambridge, MA:Harvard University Press.
33. Healy, D., 2004. Shaping the intimate:influences on the experience of everyday nerves. Social Studies of Science, 34 (2):219–245.
34. Hird, M. J., 2004. Sex, Gender and Science, New York:Palgrave MacMillan.
35. Hitt, J., 2000. The second sexual revolution. The New York Times Magazine, 20 February:34–41. 50, 62, 64, 68–69
36. Hoberman, J., 2005. Testosterone Dreams:Rejuvenation, Aphrodisia, Doping, Berkeley, CA:University of California Press.
37. Illich, I., 1976. Medical Nemesis:The Expropriation of Health, New York:Random House.
38. Kaplan, S. A., Reis, R. B., Kohn, I. J., Ikeguchi, E. F., Laor, E., Te, A. E., and Martins, A. C. P., 1999. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology, 53:481–486.
39. Katz, S., and Marshall, B. L., 2004. Is the functional ‘normal’? Aging, sexuality and the biomarking of successful living. History of the Human Sciences, 17 (1):53–75.
40. Koch, P. B., Mansfield, P. K., and Wood, J. M., 2006. Women's sexual desire:a feminist critique. Journal of Sex Research, 43:236–244.
41. Kramer, P., 1993. Listening to Prozac:A Psychiatrist Explores Antidepressant Drugs and the Remaking of the Self, New York:Penguin/Viking.
42. Lakoff, A., 2006. Pharmaceutical Reason:Knowledge and Value in Global Psychiatry, Cambridge:Cambridge University Press.
43. Lee, K. C., Feldman, M. D., and Finley, P. R., 2002. Beyond depression:evaluation of newer indications and off-label uses for SSRIs. Formulary, 37 (6):312
44. Liverman, C. T., and Blazer, D. G., 2004. Testosterone and Aging:Clinical Research Directions, Edited by:Liverman, C. T., and Blazer, D. G., Washington, DC:National Academies Press, Institute of Medicine.
45. Loe, M., 2004. The Rise of Viagra:How the Little Blue Pill Changed Sex in America, New York:NYU Press.
46. Mamo, L., and Fishman, J., 2001. Potency in all the right places:Viagra as a technology of the gendered body. Body and Society, 7 (4):13–35.
47. Marshall, B. L., and Katz, S., 2002. ‘Forever functional’:sexual fitness and the aging male body. Body and Society, 8 (4):43–70.
48. Mayer, M., Stief, C. G., Truss, M. C., and Uckert, S., 2005. Phosphodiesterase inhibitors in female sexual dysfunction. World Journal of Urology, 23:393–397.
49. McLaren, A., 2007. Impotence:A Cultural History, Chicago, IL:University of Chicago Press.
50. McMahon, C., 2005. Premature ejaculation:past, present and future perspectives. Journal of Sexual Medicine, 2 (Supp. 2):94–95.
51. Morales, A., 1998. “ Preface ”. In Erectile Dysfunction:Issues in Current Pharmacotherapy, Edited by:Morales, A., xv–xvi. London:Martin Dunitz Ltd.
52. Morley, J. E., Charlton, E., Patrick, P., Kaiser, F. E., Cadeau, P., McCready, D., and Perry, H.M.I., 2000. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism, 49 (9):1239–1242.
53. Moynihan, R., and Cassels, A., 2005. Selling Sickness:How the World's Biggest Pharmaceutical Companies are Turning us All into Patients, Vancouver:Greystone Books.
54. Munarriz, R., Talakoub, L., Flaherty, E. E., Gioia, L. H., Kim, N., Traish, A., Goldstein, I., Guay, A., and Spark, R., 2002. Androgen replacement therapy with dehydroepiandrosterone for androgen insufficiency and female sexual dysfunction:androgen and questionnaire results. Journal of Sex and Marital Therapy, 28:165–173.
55. Nehra, A., Steers, W. D., Althof, S. E., Andersson, K.-E., Burnett, A., Costabile, R. A., Goldstein, I., Kloner, R. A., Lue, T. F., Morales, A., Rosen, R. C., Shabsigh, R., Siroky, M. B., and King, L., 2003. Third international conference on the management of erectile dysfunction:linking pathophysiology and therapeutic response. Journal of Urology, 170:S3–S5.
56. Nusbaum, M. R. H., and Hamilton, C. D., 2002. The proactive sexual health history. American Family Physician, 66 (9):1705–1712.
57. Park, K., Goldstein, I., Andry, C., Siroky, M. B., Krane, R. J., and Azadzoi, K. M., 1997. Vasculogenic female sexual dysfunction:the hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency. International Journal of Impotence Research, 9:27–37.
58. Payer, L., 1992. Disease-Mongering:How Doctors, Drug Companies and Insurers are Making You Feel Sick, New York:John Wiley and Sons.
59. Porter, T. M., 1995. Trust in Numbers:The Pursuit of Objectivity in Science and Public Life, Princeton, NJ:Princeton University Press.
60. Potts, A., 2000. The essence of the hard-on:hegemonic masculinity and the cultural construction of erectile dysfunction. Men and Masculinities, 3 (1):85–103.
61. Potts, A., Grace, V., Gavey, N., and Vares, T., 2004. Viagra stories’:challenging ‘erectile dysfunction. Social Science and Medicine, 59:489–499.
62. Potts, M., 2003. Two pills, two paths:a tale of gender bias. Endeavour, 27 (3):127–130.
63. Rabinow, P., 1996. Essays on the Anthropology of Reason, Princeton, NJ:Princeton University Press.
64. Radley, D. C., Finkelstein, S. N., and Stafford, R. S., 2006. Off-label prescribing among office-based physicians. Archives of Internal Medicine, 166 (9):1021–1026.
65. Richer, S., 2002. The Therapeutic Market for Male and Female Sexual Dysfunction, London:PJB Publications.
66. Rivera-Woll, L. M., Papalia, M., Davis, S. R., and Burger, H. G., 2004. Androgen insufficiency in women:diagnostic and therapeutic implications. Human Reproduction Update, 10 (5):421–432.
67. Roberts, C., 2007. Messengers of Sex:Hormones, Biomedicine and Feminism, Cambridge:Cambridge University Press.
68. Rose, N., 2003. Neurochemical selves. Society,:46–59.
69. Rose, N., 2005. Will Biomedicine Transform Society? The Political, Economic, Social and Personal Impact of Medical Advances in the Twenty-First Century, London:Clifford Barclay Lecture, London School of Economics. 2 February
70. Rose, N., 2006. Disorders without borders? The expanding scope of psychiatric practice. BioSocieties, 1:465–484.
71. Rose, N., 2007a. Beyond medicalisation. The Lancet, 369:700–702.
72. Rose, N., 2007b. Molecular biopolitics, somatic ethics and the spirit of biocapital. Social Theory and Health, 5:3–29.
73. Rose, N., 2007c. The Politics of Life Itself:Biomedicine, Power and Subjectivity in the Twenty-First Century, Princeton, NJ:Princeton University Press.
74. Rosenberg, C. E., 2002. The tyranny of diagnosis:specific entities and individual experience. The Millbrank Quarterly, 80 (2):237–260.
75. Rosenberg, C. E., 2006. Contested boundaries:psychiatry, disease and diagnosis. Perspectives in Biology and Medicine, 49 (3):407–424.
76. Segraves, R., and Woodard, T., 2006. Female hypoactive sexual desire disorder:history and current status. Journal of Sexual Medicine, 3:408–418.
77. Shabsigh, R., 1999. Efficacy of sildenafil citrate (Viagra) is not affected by aetiology of erectile dysfunction. International Journal of Clinical Practice,:19–20.
78. Spectra Intelligence. 2006. The World Market for Sexual Disorders 2005–2012:Traversing New Frontiers in Sexual Chemistry, London:Spectra Intelligence.
79. Tan, R., and Culberson, J. W., 2003. An integrative review on current evidence of testosterone replacement therapy for the andropause. Maturitas, 45:15–27.
80. Tiefer, L., 1996. The medicalization of sexuality:conceptual, normative and professional issues. Annual Review of Sex Research, 7:252–282.
81. Tiefer, L., 2000. Sexology and the pharmaceutical industry:the threat of co-optation. Journal of Sex Research, 37 (3):273–283.
82. Tiefer, L., 2006a. Female sexual dysfunction:a case study of disease mongering and activist resistance. Public Library of Science Medicine, 3 (4):1–5.
83. Tiefer, L., 2006b. The Viagra phenomenon. Sexualities, 9 (3):273–294.
84. Verit, F. F., Yeni, E., and Kafali, H., 2006. Progress in female sexual dysfunction. Urologia Internationalis, 76:1–10.
85. Wilson, E. A., 2004. Psychosomatic:Feminism and the Neurological Body, Durham, NC:Duke University Press.